|
市場調査レポート
商品コード
1402477
北米の臨床試験市場の2028年までの予測-地域別分析-試験設計、フェーズ、適応症別North America Clinical Trials Market Forecast to 2028 - Regional Analysis - by Study Design, Phase, and Indication |
||||||
|
|
|||||||
| 北米の臨床試験市場の2028年までの予測-地域別分析-試験設計、フェーズ、適応症別 |
|
出版日: 2023年10月26日
発行: The Insight Partners
ページ情報: 英文 132 Pages
納期: 即納可能
 |
- 全表示
- 概要
- 図表
- 目次
北米の臨床試験市場は、2022年の273億2,228万米ドルから2028年には368億1,815万米ドルに成長すると予測されています。2022年から2028年までのCAGRは5.1%と推定されます。
製薬業産業の繁栄と研究開発活動の活発化が北米臨床試験市場を後押し
製薬産業は、世界的に最も研究開発集約的な産業の1つです。製薬会社は研究開発が意図した目標を確実に達成することを強く望んでおり、医薬品の価値はますます重要になっています。過去10年間で、毎年承認される新薬の数も増加しています。患者のニーズを満たすために、より高い有効性と効率を達成するための努力がなされています。米国は研究開発投資の先進国であり、過去10年間に世界の新薬の半分以上を生産しました。2014年から2019年にかけて上市された新薬の売上の62.3%を米国が占めています。R&Dは、製薬会社が医学的・商業的に大きな可能性を秘めた様々な治療用途の新分子を生み出すことを可能にするものであり、製薬会社のビジネスにとって重要かつ不可欠なものです。
研究開発費は、新製品の発見、検討、製造、前払金、既存の成果の改善、発売前の製品の有効性と規制遵守の実証のために行われます。研究開発投資は臨床試験の必要性や需要によって異なります。費用には、材料、消耗品、給与のほか、品質管理の開発費用も含まれます。
北米臨床試験市場概要
北米の臨床試験市場は米国、カナダ、メキシコに区分されます。米国は最大の臨床試験市場であり、急成長しています。この地域の市場成長は、米国が臨床研究の主要な目的地として台頭していること、と臨床試験への応用のために企業が革新的なサービスを提供していることに起因しています。
米国は臨床研究の主要な目的地として浮上しています。臨床試験全体の半分近くが米国で実施されています。さらに、ほとんどの製薬研究会社は、確立された医療インフラ、迅速な承認スケジュール、有利な規制枠組み、世界的に認められた臨床試験生成データにより、米国での臨床試験の実施を好んでいます。世界保健機関（WHO）の報告書によると、米国は2021年に最も多くの臨床試験（157,618件）を登録しました。
北米の臨床試験市場の収益と2028年までの予測（金額）
北米の臨床試験市場のセグメンテーション
北米の臨床試験市場は、フェーズ、試験設計、適応症、国に区分されます。
フェーズに基づき、北米臨床試験市場はフェーズI、フェーズII、フェーズIII、フェーズIVに区分されます。第III相セグメントは2022年に北米臨床試験市場で最大のシェアを記録しました。
研究設計に基づいて、北米臨床試験市場は介入、観察、拡大アクセスに区分されます。インターベンショナルセグメントは2022年に北米臨床試験市場で最大のシェアを占めました。
適応症に基づき、北米臨床試験市場は自己免疫／炎症、疼痛管理、腫瘍、中枢神経系疾患、糖尿病、肥満、心血管、その他に区分されます。2022年の北米臨床試験市場シェアは、がん分野が最大でした。
国別に見ると、北米臨床試験市場は米国、カナダ、メキシコに分類されます。米国は2022年の北米臨床試験市場シェアを独占しました。
Charles River Laboratories International Inc、ICON Plc、IQVIA Holdings Inc、IXICO Plc、Laboratory Corp of America Holdings、Parexel International Corp、SGS SA、Syneos Health Inc、Thermo Fisher Scientific Inc、WuXi AppTec Co Ltd.は、北米臨床試験市場で事業を展開する大手企業の一部です。
目次
第1章 イントロダクション
第2章 キーポイント
第3章 調査手法
- カバー範囲
- 2次調査
- 1次調査
第4章 北米臨床試験市場-市場情勢
- イントロダクション
- PEST分析
- 北米PEST分析
- 専門家の見解
第5章 北米の臨床試験市場-主要市場力学
- 市場の促進要因
- 臨床試験の採用とアウトソーシングの増加
- 製薬業界の繁栄と研究開発活動の活発化
- 市場抑制要因
- 高価で時間のかかるプロセス
- 市場機会
- 分散型臨床試験とハイブリッド臨床試験の採用
- 今後の動向
- AI主導治験
- 影響分析
第6章 臨床試験市場-北米分析
- 北米臨床試験市場の収益予測と分析
第7章 北米臨床試験市場の収益と2028年までの予測：試験設計別
- イントロダクション
- 北米の臨床試験市場、フェーズ別、2022年と2028年（%）
- 介入試験
- 観察研究
- 拡大アクセス
第8章 北米臨床試験市場：フェーズ別
- イントロダクション
- 北米の臨床試験市場、フェーズ別、2022年と2028年（%）
- フェーズIII
- フェーズII
- フェーズIV
- フェーズI
第9章 北米の臨床試験市場の収益と2028年までの予測：適応症別
- イントロダクション
- 北米臨床試験市場の適応症別売上高シェア（2022年、2028年）
- 自己免疫/炎症
- 疼痛管理
- 腫瘍学
- 中枢神経系疾患
- 糖尿病
- 肥満症
- 心血管
- その他
第10章 北米の臨床試験市場：2028年までの収益と予測：国別分析
- 北米
第11章 業界情勢
- イントロダクション
- 市場参入企業の成長戦略（%）
- 有機的展開
- 概要
- 無機的展開
- 概要
第12章 企業プロファイル
- IQVIA Holdings Inc
- Parexel International Corp
- IXICO Plc
- Charles River Laboratories International Inc
- ICON Plc
- WuXi AppTec Co Ltd
- SGS SA
- Syneos Health Inc
- Thermo Fisher Scientific Inc
- Laboratory Corp of America Holdings
第13章 付録
List Of Tables
- Table 1. US Clinical Trials Market, by Phase - Revenue and Forecast to 2028 (US$ Million)
- Table 2. US Clinical Trials Market, by Study Design - Revenue and Forecast to 2028 (US$ Million)
- Table 3. US Clinical Trials Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
- Table 4. Canada: Clinical Trials Market, by Phase - Revenue and Forecast to 2028 (US$ Million)
- Table 5. Canada: Clinical Trials Market, by Study Design - Revenue and Forecast to 2028 (US$ Million)
- Table 6. Canada: Clinical Trials Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
- Table 7. Mexico: Clinical Trials Market, by Phase - Revenue and Forecast to 2028 (US$ Million)
- Table 8. Mexico: Clinical Trials Market, by Study Design - Revenue and Forecast to 2028 (US$ Million)
- Table 9. Mexico: Clinical Trials Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
- Table 10. Organic Developments Done by Companies
- Table 11. Inorganic Developments Done by Companies
- Table 12. Glossary of Terms
List Of Figures
- Figure 1. North America Clinical Trials Market Segmentation
- Figure 2. North America Clinical Trials Market, By Country
- Figure 3. North America Clinical Trials Market Overview
- Figure 4. Phase III Segment Held Largest Share of Phase Segment in North America Clinical Trials Market
- Figure 5. Canada is Expected to Show Remarkable Growth During the Forecast Period
- Figure 6. North America: PEST Analysis
- Figure 7. North America Experts Opinion
- Figure 8. Impact Analysis
- Figure 9. North America Clinical Trials Market- Revenue Forecast and Analysis - 2020- 2028
- Figure 10. North America Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
- Figure 11. Interventional: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 12. Observational: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 13. Expanded Access: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 14. North America Clinical Trials Market, by Phase 2022 and 2028 (%)
- Figure 15. Phase III: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 16. Phase II: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 17. Phase IV: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 18. Phase I: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 19. North America Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
- Figure 20. Autoimmune/Inflammation: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 21. Pain Management: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 22. Oncology: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 23. CNS Condition: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 24. Diabetes: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 25. Obesity: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 26. Cardiovascular: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 27. Other: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 28. North America: Clinical Trials Market, by Key Country - Revenue (2022) (US$ Million)
- Figure 29. North America: Clinical Trials Market, by Country, 2022 & 2028 (%)
- Figure 30. US: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 31. Canada: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 32. Mexico: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- Figure 33. Growth Strategies Done by the Companies in the Market, (%)
The North America clinical trials market is expected to grow from US$ 27,322.28 million in 2022 to US$ 36,818.15 million by 2028. It is estimated to grow at a CAGR of 5.1% from 2022 to 2028.
Flourishing Pharmaceutical Industry and Increasing R&D Activities in Pharmaceutical Industry Fuels North America Clinical Trials Market
The pharmaceutical industry is one of the most R&D-intensive industries globally. The value of medicines is becoming increasingly important as pharmaceutical companies are keen to ensure that R&D achieves their intended goal. Over the last decade, the number of new drugs approved yearly has also increased. Efforts are being made to achieve greater effectiveness and efficiency in fulfilling patients' needs. The US is a leading country in R&D investments, producing over half of the world's new molecules in the past decade. The US accounted for 62.3% of sales of new medicines launched during 2014-2019. R&D is a significant and essential part of the business of pharmaceutical companies as it enables them to come up with new molecules for various therapeutic applications with significant medical and commercial potential.
R&D expenditure is done to discover, examine, and produce new products; upfront payments; improve existing outcomes; and demonstrate product efficacy and regulatory compliance before launch. The R&D investments differ as per the need and demand for clinical trials. The cost includes materials, supplies used, and salaries, along with the cost of developing quality control.
North America Clinical Trials Market Overview
The North America clinical trials market is segmented into the US, Canada, and Mexico. The US is the largest and fastest-growing market for clinical trials. The market growth in the region is accredited to the US emerging as a leading clinical research destination and the innovative services offered by companies for applications in clinical trials.
The US has emerged as a leading clinical research destination. Nearly half of the total clinical trials are conducted in the US. Additionally, most pharma research companies prefer to perform clinical trials in the US owing to established medical infrastructure, fast approval timelines, a favorable regulatory framework, and accepted clinical trial generated data globally. A World Health Organization (WHO) report states that the US registered the highest number of clinical trials (157,618) in 2021.
North America clinical Trials Market Revenue and Forecast to 2028 (US$ Million)
North America Clinical Trials Market Segmentation
The North America clinical trials market is segmented into phase, study design, indication, and country.
Based on phase, the North America clinical trials market is segmented into phase I, phase II, phase III, and phase IV. The phase III segment registered the largest North America clinical trials market share in 2022.
Based on study design, the North America clinical trials market is segmented into interventional, observational, and expanded access. The interventional segment held the largest North America clinical trials market share in 2022.
Based on Indication, the North America clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular, and others. The oncology segment held the largest North America clinical trials market share in 2022.
Based on country, the North America clinical trials market has been categorized into the US, Canada, and Mexico. The US dominated the North America clinical trials market share in 2022.
Charles River Laboratories International Inc, ICON Plc, IQVIA Holdings Inc, IXICO Plc, Laboratory Corp of America Holdings, Parexel International Corp, SGS SA, Syneos Health Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd. are some of the leading companies operating in the North America clinical trials market.
Reasons to Buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America clinical trials market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America clinical trials market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the clinical trials market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
Table Of Contents
1. Introduction
- 1.1 Scope of the Study
- 1.2 The Insight Partners Research Report Guidance
- 1.3 Market Segmentation
- 1.3.1 North America Clinical Trials Market - By Phase
- 1.3.2 North America Clinical Trials Market - By Study Design
- 1.3.3 North America Clinical Trials Market - By Indication
- 1.3.4 North America Clinical Trials Market - By Country
2. Key Takeaways
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. North America Clinical Trials Market - Market Landscape
- 4.1 Overview
- 4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
- 4.3 Experts Opinion
5. North America Clinical Trials Market - Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Increasing Adoption and Outsourcing of Clinical Trials
- 5.1.2 Flourishing Pharmaceutical Industry and Increasing R&D Activities in Pharmaceutical Industry
- 5.2 Market Restraints
- 5.2.1 Expensive and Time-Consuming Process
- 5.3 Market Opportunities
- 5.3.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials
- 5.4 Future Trends
- 5.4.1 AI-Driven Clinical Trials
- 5.5 Impact Analysis
6. Clinical Trials Market - North America Analysis
- 6.1 North America Clinical Trials Market Revenue Forecast and Analysis
7. North America Clinical Trials Market Revenue and Forecast To 2028 - by Study Design
- 7.1 Overview
- 7.2 North America Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
- 7.3 Interventional
- 7.3.1 Overview
- 7.3.2 Interventional: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 7.4 Observational
- 7.4.1 Overview
- 7.4.2 Observational: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 7.5 Expanded Access
- 7.5.1 Overview
- 7.5.2 Expanded Access: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
8. North America Clinical Trials Market - By Phase
- 8.1 Overview
- 8.2 North America Clinical Trials Market, by Phase, 2022 and 2028 (%)
- 8.3 Phase III
- 8.3.1 Overview
- 8.3.2 Phase III: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 8.4 Phase II
- 8.4.1 Overview
- 8.4.2 Phase II: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 8.5 Phase IV
- 8.5.1 Overview
- 8.5.2 Phase IV: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 8.6 Phase I
- 8.6.1 Overview
- 8.6.2 Phase I: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
9. North America Clinical Trials Market Revenue and Forecast To 2028 - Indication
- 9.1 Overview
- 9.2 North America Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
- 9.3 Autoimmune/Inflammation
- 9.3.1 Overview
- 9.3.2 Autoimmune/Inflammation: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 9.4 Pain Management
- 9.4.1 Overview
- 9.4.2 Pain Management: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 9.5 Oncology
- 9.5.1 Overview
- 9.5.2 Oncology: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 9.6 CNS Condition
- 9.6.1 Overview
- 9.6.2 CNS Condition: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 9.7 Diabetes
- 9.7.1 Overview
- 9.7.2 Diabetes: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 9.8 Obesity
- 9.8.1 Overview
- 9.8.2 Obesity: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 9.9 Cardiovascular
- 9.9.1 Overview
- 9.9.2 Cardiovascular: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 9.10 Other
- 9.10.1 Overview
- 9.10.2 Other: North America Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
10. North America Clinical Trials Market - Revenue and Forecast to 2028 - Country Analysis
- 10.1 North America: Clinical Trials Market
- 10.1.1 Overview
- 10.1.2 North America: Clinical Trials Market, by Country, 2022& 2028 (%)
- 10.1.2.1 US: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.2.1.1 Overview
- 10.1.2.1.2 US: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.2.1.3 US: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
- 10.1.2.1.4 US: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
- 10.1.2.1.5 US: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)
- 10.1.2.2 Canada: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.2.2.1 Overview
- 10.1.2.2.2 Canada: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.2.2.3 Canada: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
- 10.1.2.2.4 Canada: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
- 10.1.2.2.5 Canada: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)
- 10.1.2.3 Mexico: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.2.3.1 Overview
- 10.1.2.3.2 Mexico: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
- 10.1.2.3.3 Mexico: Clinical Trials Market, by Phase, 2020-2028 (US$ Million)
- 10.1.2.3.4 Mexico: Clinical Trials Market, by Study Design, 2020-2028 (US$ Million)
- 10.1.2.3.5 Mexico: Clinical Trials Market, by Indication, 2020-2028 (US$ Million)
- 10.1.2.1 US: Clinical Trials Market - Revenue and Forecast to 2028 (US$ Million)
11. Industry Landscape
- 11.1 Overview
- 11.2 Growth Strategies Done by the Companies in the Market, (%)
- 11.3 Organic Developments
- 11.3.1 Overview
- 11.4 Inorganic Developments
- 11.4.1 Overview
12. Company Profiles
- 12.1 IQVIA Holdings Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Parexel International Corp
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 IXICO Plc
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Charles River Laboratories International Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
- 12.5 ICON Plc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 WuXi AppTec Co Ltd
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 SGS SA
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 Syneos Health Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 Thermo Fisher Scientific Inc
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
- 12.10 Laboratory Corp of America Holdings
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments
13. Appendix
- 13.1 About The Insight Partners
- 13.2 Glossary of Terms
